Subscribe to Newsletter
Techniques & Tools Pharma & Biopharma, Spectroscopy

Mirror, Mirror…

Many drugs are chiral molecules, which means that they have the potential to “flip” and exist as different enantiomers – non-superimposable mirror images of the original molecule with an identical chemical structure. In some cases, this flipping behavior can occur when an enantiomerically pure drug enters the body – a process known as racemization. Recent research aims to predict racemization (1), so we spoke to co-author Niek Buurma from Cardiff University’s School of Chemistry to discover more about the dangers of mirror molecules – and a new tool to remedy the problem.

Why is racemization a problem?

The pharmaceutical action of a significant fraction of all drugs depends on administering the correct enantiomer. When we administer a mixture of enantiomers, one of the enantiomers will act as intended, but the other doesn’t fit with the target, which can lead to binding to unintended targets and potentially serious side effects. If racemization is discovered late in the drug discovery process, the compound may turn into an expensive blind alley.

These days, everyone is aware of the need to administer single-enantiomer drugs. But until now, there were no good models to quantitatively predict how these enantiomers would behave once exposed to the aqueous conditions in the body.

How can your model help?

Using circular dichroism and H NMR spectroscopy to measure the kinetics for racemization of 28 compounds, we (along with Andrew Leach, from Liverpool John Moores University) have developed a predictive model that allows efficient quantitative prediction of racemization risk. Essentially, it allows researchers in academia and industry to identify molecules at risk of racemization at a very early stage. Not only does this help avoid dead-end research and development pathways, but it also allows researchers to “design out” racemization risk by exploring the effect of changes to the molecular structure. In addition, we present a series of different experimental approaches to confirm whether a potential drug racemizes under physiological conditions.

What’s next?

We are now developing a version of the model that predicts the risk of racemization during typical reaction workup procedures. Our guidelines and predictive models provide a solid approach to predicting racemization, and we would like to see our quantitative predictions and experimental tests incorporated as standard in the drug discovery pipeline.

Receive content, products, events as well as relevant industry updates from The Analytical Scientist and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. A Ballard et al., “Quantitative prediction of rate constants for aqueous racemization to avoid pointless stereoselective syntheses”, Angew Chem Int Ed, 57, 982 (2018).
About the Author
Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as an Associate Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Related Application Notes
Safer AAV Analysis with Non-toxic AEX Method

| Contributed by Tosoh

Novel Approaches to Measure Receptor-Mediated Endocytosis of Herceptin-GB05N0009I

| Contributed by Zeiss

Non-targeted profiling of polar metabolites in human plasma

| Contributed by YMC

Related Product Profiles
Higher Peaks – Clearly.

| Contributed by Shimadzu Europa

Compact with countless benefits

| Contributed by Shimadzu Europa

The fine Art of Method Development

| Contributed by Shimadzu Europa

Register to The Analytical Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Analytical Scientist magazine

Register